Results 231 to 240 of about 31,914 (284)

Non-Vitamin K Antagonist Oral Anticoagulants [PDF]

Chest, 2014
E. Shantsila, G. Lip
semanticscholar   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Reversal agents for non-vitamin K antagonist oral anticoagulants

Nature Reviews Cardiology, 2018
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa. Although clinical studies of NOACs were conducted without antidotes, patient outcomes with major bleeding when receiving NOACs were no worse than those in ...
J. Levy, J. Douketis, J. Weitz
semanticscholar   +3 more sources

Non-vitamin K antagonist oral anticoagulants and sport

Minerva Cardioangiologica, 2020
Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical ...
Romano S., Salustri E., Robles A. G., Calo L., Penco M., Sciarra L.   +5 more
openaire   +2 more sources

Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

Hämostaseologie, 2021
AbstractThe prevention of atherothrombotic events is the primary goal in the treatment of patients with arteriosclerotic disorders. Despite recent improvements in the management of coronary artery disease (CAD) with revascularization techniques and antiplatelet therapy, some patients remain at risk of recurrent cardiovascular events.
Samer, Al Said, Michael, Ellscheid, Eleftherios T, Beltsios, Norbert, Frey   +3 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants and infective endocarditis

Heart, 2018
To the Editor  We read with great interest the Editorial by Erwin and Lung, which stated that in patients treated with oral anticoagulants and concomitant infective endocarditis, it is recommended to switch/bridge with heparin in the first 2 weeks to decrease the bleeding risk if cerebral embolism occurs, particularly in staphylococcal endocarditis.1 ...
Caldeira, Daniel, Ferreira, Joaquim J, Pinto, Fausto J., Costa, João   +3 more
openaire   +3 more sources

Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

Hematology/Oncology Clinics of North America, 2016
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF.
Anna, Plitt, Christian T, Ruff, Robert P, Giugliano   +2 more
openaire   +2 more sources

Converting patients from warfarin to non-vitamin K antagonist oral anticoagulants

Journal of the American Association of Nurse Practitioners, 2023
ABSTRACT Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are favorable in stroke prevention for geriatric patients with nonvalvular atrial fibrillation versus warfarin. These anticoagulants do not require international normalized ratio (INR) monitoring and have lower food/drug interactions.
Sarah Romanelli, Veronica Rivera
openaire   +2 more sources

Safety of non-vitamin K antagonist oral anticoagulants - coronary risks

Expert Opinion on Drug Safety, 2016
Since the approval and commercialization of non-vitamin K antagonist oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban, and rivaroxaban) several studies and meta-analyses have raised safety concerns regarding myocardial infarction (MI) risk among NOAC-treated patients, particularly with dabigatran.
Daniel, Caldeira, Joaquim J, Ferreira, Fausto J, Pinto, João, Costa   +3 more
openaire   +2 more sources

Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral Anticoagulants

Seminars in Thrombosis and Hemostasis, 2015
Anticoagulant treatment can be currently instituted with two different classes of drugs: the vitamin K antagonists (VKAs) and the newer, "novel" or non-vitamin K antagonist oral anticoagulant drugs (NOACs). The NOACs have several practical advantages over VKAs, such as the rapid onset/offset of action, the lower potential for food and drug interactions,
RIVA, NICOLETTA, AGENO, WALTER
openaire   +4 more sources

Misdosing of Non–Vitamin K Antagonist Oral Anticoagulants in Primary Care

Clinical Therapeutics, 2020
Prescription patterns of non-vitamin K antagonist oral anticoagulants (NOACs) are unknown among primary care physicians, where most patients with nonvalvular atrial fibrillation (NVAF) are diagnosed and followed up. The goal of this study was to evaluate overdosing and underdosing of NOACs in patients with NVAF followed up in primary care and determine
Carlos Seiça, Cardoso, João André, Sousa, Pedro, Simões, Beatriz, Silva, Ana, Albuquerque, Ana, Esperança, Ana, Cibrão, Artur, Correia, Joana, Gonçalves, Joana, Mortágua, José Eduardo, Almeida, Leonor, Oliveira, José, Garcia, Mariana, Duarte, Mariana, Loureiro, Marta, Costa E Silva, Marta, Fraga, Paulo, Lopes, Rui, Brandão, Susana, Miguel, Teresa, Queirós, Gustavo, Santo, Fernando, Silva, João, Sargento-Freitas   +23 more
openaire   +2 more sources